Answers are grounded in this paper and cite their sources.
// Tao Wang 1, 2 , Xiangyun Qu 1 , Jiajia Jiang 3 , Peng Gao 1 , Dingding Zhao 1 , Xueqi Lian 3 and Xiaohua Li 3, 4 1 Key Laboratory of PreMed Precision Medicine, Soochow University, Suzhou, 215121, China 2 Jiangsu Provincial Key Laboratory of Molecular Biology and Translational Medicine of Malignant Tumor, Suzhou, 215123, China 3 Affiliated AoYang Hospital of Jiangsu University, Zhangjiagang, Suzhou, 215600, China 4 Nanjing Medical University, Nanjing, 211166, China Correspondence to: Xiaohua Li, email: joshua28li@163.com Keywords: prostate cancer antigen 3, prostate-specific antigen, prostate cancer, diagnostic signature, cell-free Received: November 01, 2016 Accepted: March 31, 2017 Published: April 20, 2017 ABSTRACT Prostate cancer antigen 3(PCA3) is a long non-coding RNA, which was found increased expression in CaP patients than healthy individual. In this study, the individual nucleic acid of PCA3 and PSA was recombinant expressed as a reference reagent, and a quantitative RT-PCR with TaqMan assay was developed to examine the copies of PCA3 and PSA gene in urine. The results showed that the area under the receiver operating characteristic curve (AUROC) was 0.717, 0.444 and 0.916 for the number of PCA3 copy, PSA copy and for the score of PCA3/PSA RNA, respectively. Additionally, the AUROC for serum tPSA was 0.674 with a low specificity of 12.07%. Finally, the algorithm of PCA3 RNA versus PSA RNA was evaluated and corroborated as CaP biomarker by conducting a multicentric clinical trial. This study not only validated the developed technique of qRT-PCR with TaqMan assay for examination of urinary PCA3 and PSA RNA, it also demonstrated that the score of the PCA/PSA RNA was a reliable signature for CaP diagnosis.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: